|
SGNBCMA-001: A phase 1 study of SEA-BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Loxo |
|
Speakers' Bureau - Celgene |
Research Funding - Seagen (Inst) |
|
|
Consulting or Advisory Role - Amgen; Flatiron Health; Incyte; Partners Therapeutics; Pfizer; Sanofi |
Speakers' Bureau - Merck; Takeda |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Seagen |
|
|
|
Stock and Other Ownership Interests - Seagen |
Travel, Accommodations, Expenses - Seagen |
|
|
|
Stock and Other Ownership Interests - Seagen |
|
|
|
Stock and Other Ownership Interests - Seagen |